20
Minority Accruals to Clinical Trials PAN Annual Meeting April 2014 Suzanne Grant, Director of Strategic Communications Kelly Cunha, Manager of Marketing and Web Strategy

Moffitt minority accruals to clinical trials

Embed Size (px)

Citation preview

Page 1: Moffitt minority accruals to clinical trials

Minority Accruals to Clinical Trials

PAN Annual Meeting

April 2014

Suzanne Grant, Director of Strategic Communications

Kelly Cunha, Manager of Marketing and Web Strategy

Page 2: Moffitt minority accruals to clinical trials

Outl ine

• What and Where is Moffitt?

• Clinical Trial Accrual Summary

• Minority Accrual Efforts; Task Forces

• Moffitt Clinical Trial Funding Opportunity

Page 3: Moffitt minority accruals to clinical trials

What is Moffitt?

• Established by the Florida Legislature in 1981 to address the burden of cancer in Florida. Opened in 1986.

• Located in Tampa, Fla.

• Named after H. Lee Moffitt, former Speaker of the Florida House of Representatives and the impetus behind the Center.

Page 4: Moffitt minority accruals to clinical trials

Florida – PSA/SSA Region

Hillsborough

Sarasota

Manatee

Hernando

Pasco

Polk

Pinellas

M

Page 5: Moffitt minority accruals to clinical trials

Market Demographics Snapshot

Source: Corporate Planning, Catchment Area: Hillsborough, Pasco, Pinellas, Polk, Hernando, Manatee, Sarasota Counties. See Methodology for further detail. Demographics represent all ages.

Page 6: Moffitt minority accruals to clinical trials

A Closer Look at Minori ty Data

Hispanic or Latino Black/African American0.00%

2.00%

4.00%

6.00%

8.00%

10.00%

12.00%

14.00%

16.00%

18.00%16.55%

11.45%

5.35%

6.74%7.72%

5.89%

2012 Population 2011 Total Cancer Cases 2011 Moffitt Cancer Cases

Page 7: Moffitt minority accruals to clinical trials

0%

2%

4%

6%

8%

10%

12%

14%

16%

18%

16.55% (Peds 4.98%)

5.35%

7.72%

5.21% 5.57%

7.59%6.29%

5.16%

Therapeutic Trial Accruals Hispanic/Lat ino

Page 8: Moffitt minority accruals to clinical trials

← Moffitt Accrual →MoffittCases

CatchmentPopulation

CatchmentCases

2012 2011 2011 2009 2010 2011 2012 2013

0%

2%

4%

6%

8%

10%

12%

14%

11.45% (Peds 3.62%)

6.74% 5.89%

3.44%4.23%

5.18% 5.18%

3.79%

Therapeutic Trial Accruals Afr ican American

Page 9: Moffitt minority accruals to clinical trials

What and Why?

Goal: • Surpass percentage of minority patients in trials to cancer

cases in catchment

Strategy:• Formal committee structure with financial support

• Retreat held resulting in 5 areas of focus; task forces for each area

Page 10: Moffitt minority accruals to clinical trials

Task Force 1- Educating referr ing physicians and partners

Page 11: Moffitt minority accruals to clinical trials

Task Force 2- Educating Moff i t t workforce; nursing focus

Page 12: Moffitt minority accruals to clinical trials

Task Force 3- Patient Navigat ion

Developed social work-clinical trials collaboration for Patient Navigation targeting African-American and bilingual/Hispanic/Latino

• Culturally sensitive• Professionally adept• Resourceful and independent

• Target GI, GU and Hem

• Added Language Services Personnel• Support compliance, ops, clinic, marketing

Page 13: Moffitt minority accruals to clinical trials

Task Force 4- Physician education and researcher review• Report card to chairs

• Monthly and YTD accrual by department and investigator

• Mandatory MD Lecture Series• 26 topics identified – 50% mandatory • Topics:

• Minority focused: Language barriers, cultural competency

• Regulatory aspects: trial design, informed consent, etc.

Page 14: Moffitt minority accruals to clinical trials

Task Force 5- Minori ty Community Reputat ion Enhancement

• Focus groups & research led by minority-owned agencies• Right channel/mediums for the communities• Focus on meaningful/memorable communication for each audience

• Testimony, layman’s terms, relevant, faces of diversity• Accelerate Community Relations efforts

Page 15: Moffitt minority accruals to clinical trials
Page 16: Moffitt minority accruals to clinical trials

Clin ical Tr ia l Funding Opportuni ty

• Phase 0, I or II trial addressing underrepresented population and likely to help increase minority subject accrual

• Priority for team science proposals including Basic or Population science• Up to $100k for trial and additional $50k for correlative science

Page 17: Moffitt minority accruals to clinical trials

QUESTIONS?

Page 18: Moffitt minority accruals to clinical trials

A Closer Look at Minori ty Data

Page 19: Moffitt minority accruals to clinical trials

Populat ion Snapshot 2012

Page 20: Moffitt minority accruals to clinical trials